Pediatric Neuroblastoma - Healing Genes

Pediatric Neuroblastoma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma

Phase 1


Researchers at Texas Children’s Hospital seek children with neuroblastoma to trial an investigatory treatment that gene-modifies their own immune natural killer T cells (NKT) to add 3 genes:

  • A gene to produce molecules on their surface that recognize neuroblastoma cells
  • A gene to make the NKT cells live longer
  • A gene to produce Interleukin 15 (IL-15) which stimulates immune response to tumors

After leukapheresis to collect the T-cells, they are gene-modified in the lab, then returned to the patient following chemotherapy. Follow up may continue for up to 15 years.


  • Be 1 to 21 years of age
  • Have relapsed or refractory high risk neuroblastoma
  • Life expectancy of at least 12 weeks
  • Weigh greater than 12kg


  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to isolate T-cells which are then modified in the lab.
  3. Chemotherapy for 3 days.
  4. The gene-modified T cells will be administered through an IV line following a day of rest.
  5. Follow up will be required for 15 years.

The study site is at Texas Children’s Hospital in Houston, TX Map.

Andras Heczey, MD    |  832-824-4233  |  [email protected]
Josalind Randall  |  832-824-6835  |  [email protected]
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine
Texas Children’s Hospital
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader